Eidos Therapeutics, Inc. Common Stock
EIDX
EIDX was delisted on the 25th of January, 2021.
89 hedge funds and large institutions have $608M invested in Eidos Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 31 reducing their positions, and 26 closing their positions.
24% more call options, than puts
Call options by funds: $5.4M | Put options by funds: $4.34M
10% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 31
12% less capital invested
Capital invested by funds: $693M → $608M (-$84.9M)
13% less funds holding
Funds holding: 102 → 89 (-13)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
50% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$30.8M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$10.9M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$4.96M |
| 4 |
BlackRock
New York
|
+$4.78M |
| 5 |
Aviva
London,
United Kingdom
|
+$3.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.4M |
| 2 |
Holocene Advisors
New York
|
-$9.62M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$6.43M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$3.63M |
| 5 |
CAC
Cowen and Company
New York
|
-$2.69M |
EIDX Hedge Fund Activity: Q1 2020 in Review
89 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q1 2020, worth a combined $608M — down 12% from $693M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of EIDX and 13 opened new positions — a net loss of 13 holders — while 31 trimmed existing stakes and 28 added.
The largest buyer was Cormorant Asset Management, adding an estimated $30.8M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $10.4M sold.
- 89 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q1 2020, down from 102 in Q4 2019.
- Funds reported $608M of Eidos Therapeutics, Inc. Common Stock stock for Q1 2020, down 12% quarter-over-quarter.
- 13 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q1 2020 and 26 closed out, a net change of -13 holders.
- The largest Eidos Therapeutics, Inc. Common Stock buyer in Q1 2020 was Cormorant Asset Management, an estimated $30.8M added.
- The largest Eidos Therapeutics, Inc. Common Stock seller in Q1 2020 was Point72 Asset Management, an estimated $10.4M sold.
Based on aggregated 13F filings for Q1 2020.